BioStock published an article on 10 November 2022 about Aptahem, which can be read in full below. Biotechnology company Aptahem’s report for the third quarter of 2022 focuses on the progress made on the way to the major milestone,...
Read MoreBioStock published an article on 31 October 2022 about Aptahem, which can be read in full below. Aptahem is nudging closer to its biggest milestone as a listed biotech company – the first clinical studies with Apta-1, a drug...
Read MoreBioStock published an article on 26 September 2022 about Aptahem, which can be read in full below. Aptahem has submitted applications to the regulatory authorities and to the Central Ethics Committee in the Netherlands for permission to start a...
Read MoreAptahem AB (publ) announce today that applications to the regulatory authority and the central ethics committee in The Netherlands have been submitted for approval to initiate a clinical phase 1 study with its drug candidate Apta-1. Aptahem develop Apta-1...
Read MoreBioStock published an article on 16 September 2022 about Aptahem, which can be read in full below. Sepsis is a life-threatening condition. Every year, 50 million people are affected by sepsis, of which 11 million die. Despite this, a...
Read MoreBioStock published an article on 31 August 2022 about Aptahem, which can be read in full below. Malmö-based biotech Aptahem, which is developing the drug candidate Apta-1 as a new type of emergency treatment for sepsis, released its Q2...
Read MoreBioStock published an article on 15 August 2022 about Aptahem, which can be read in full below. BioStock reached out to Malmö company Aptahem, which is developing an emergency treatment for sepsis. The biotech points out that they continue...
Read MoreAptahem AB (publ) announces today that the final study report from the GLP (Good Laboratory Practice) toxicology and safety studies has been finalized. The report confirms the previously communicated preliminary results regarding positive safety profile for Apta-1. The GLP...
Read MoreBioStock published an article on 17 June 2022 about Aptahem, which can be read in full below. Aptahem has appointed Dr Ingela Hallberg as the new Medical Director. The company is thus putting another piece of the puzzle in...
Read MoreAptahem (publ) announces today that Ingela Hallberg has been appointed new Chief Medical Officer (CMO) in the company as of 1 June 2022. Ingela has long and solid experience from the pharmaceutical industry where she has held senior management...
Read More